Public Sector Pension investment Board increased its position in shares of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) by 33.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 642,017 shares of the specialty pharmaceutical company’s stock after acquiring an additional 160,000 shares during the quarter. Public Sector Pension investment Board owned approximately 0.18% of Valeant Pharmaceuticals International worth $11,143,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently modified their holdings of the company. Gruss & Co. Inc. purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at about $104,000. Harbor Advisors LLC purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at about $110,000. NEXT Financial Group Inc raised its holdings in Valeant Pharmaceuticals International by 6.2% in the 2nd quarter. NEXT Financial Group Inc now owns 10,303 shares of the specialty pharmaceutical company’s stock valued at $178,000 after buying an additional 600 shares during the period. Financial Architects Inc raised its holdings in Valeant Pharmaceuticals International by 10.5% in the 2nd quarter. Financial Architects Inc now owns 10,550 shares of the specialty pharmaceutical company’s stock valued at $183,000 after buying an additional 1,000 shares during the period. Finally, WMS Partners LLC purchased a new stake in Valeant Pharmaceuticals International in the 1st quarter valued at about $116,000. Hedge funds and other institutional investors own 50.47% of the company’s stock.

Several brokerages recently issued reports on VRX. BMO Capital Markets restated a “hold” rating and issued a $15.00 price objective on shares of Valeant Pharmaceuticals International in a report on Thursday, July 27th. Zacks Investment Research upgraded shares of Valeant Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Thursday, July 27th. J P Morgan Chase & Co set a $10.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. Deutsche Bank AG set a $19.00 price objective on shares of Valeant Pharmaceuticals International and gave the company a “hold” rating in a report on Monday, July 17th. Finally, Stifel Nicolaus restated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday, June 30th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. Valeant Pharmaceuticals International currently has a consensus rating of “Hold” and a consensus target price of $17.62.

In other news, Director Schutter Richard U. De purchased 10,000 shares of the stock in a transaction dated Monday, August 21st. The stock was acquired at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the acquisition, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The acquisition was disclosed in a filing with the SEC, which is available at this link. 5.87% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece of content was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another website, it was copied illegally and republished in violation of international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/public-sector-pension-investment-board-purchases-160000-shares-of-valeant-pharmaceuticals-international-inc-vrx/1580068.html.

Shares of Valeant Pharmaceuticals International, Inc. (VRX) opened at 14.2399 on Friday. The stock has a 50 day moving average price of $14.22 and a 200 day moving average price of $13.18. Valeant Pharmaceuticals International, Inc. has a 12-month low of $8.31 and a 12-month high of $27.84. The firm’s market capitalization is $4.96 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last issued its quarterly earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The business had revenue of $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. During the same period in the previous year, the business earned ($0.88) EPS. The business’s quarterly revenue was down 7.7% on a year-over-year basis. Equities analysts anticipate that Valeant Pharmaceuticals International, Inc. will post $3.89 earnings per share for the current fiscal year.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.